Summer of 2020, Emergency Medicine Research Office (EMRO) as well as multiple investigators, site staff, organization and external organizations participated in the ACTT-2 Trial. Their hard work and data resulted in the May 11, 2022 announcement from Lilly that the US FDA gave full approval for baricitinib (OLUMIANT®) for the treatment of hospitalized patients with COVID-19.

See link below:
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19 | Eli Lilly and Company

A large part of the data supporting this approval was based on ACTT-2.

There are only two FDA approved drugs for treatment of COVID-19: remdesivir and baricitinib. ACTT played a critical role in each of these.

Congratulations to all!